IGIB 📈 iShares 5-10 Year - Overview

Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US4642886380 • Corporate Bond

IGIB: Bonds, Corporate, Debt, Securities, Futures, Options, Swaps

The iShares 5-10 Year Investment Grade Corporate Bond ETF, listed on NASDAQ under the ticker IGIB, is designed to track a specific index, with a minimum of 80% of its assets invested in the component securities of that index. This strategic allocation is intended to closely mirror the performance of the underlying index, providing investors with exposure to a diversified portfolio of investment-grade corporate bonds. By focusing on bonds with 5-10 year maturities, the fund offers a targeted approach to fixed income investing, which can be particularly appealing to investors seeking regular income and relatively lower risk.

Furthermore, the fund's investment strategy involves allocating at least 90% of its assets in fixed income securities that are of the types included in the underlying index. This approach is complemented by the ability to invest up to 10% of its assets in derivatives such as futures, options, and swaps contracts, as well as in other fixed income securities not included in the index, provided these investments are believed to enhance the fund's ability to track the index. This flexibility allows the fund manager, BFA, to employ a range of strategies to optimize the fund's performance and maintain its tracking efficiency. The fund is categorized as a corporate bond ETF, with the ISIN US4642886380, and is domiciled in the United States.

As an exchange-traded fund (ETF), IGIB offers the benefits of transparency, liquidity, and diversification, making it an attractive option for investors seeking to add a corporate bond component to their portfolios. The fund's investment grade focus ensures that it invests in bonds issued by companies with strong credit profiles, which can help mitigate default risk. By tracking an index of 5-10 year investment-grade corporate bonds, the fund provides a straightforward way for investors to gain exposure to this segment of the bond market, potentially benefiting from the regular income streams and the relatively lower volatility associated with investment-grade corporate bonds.

Additional Sources for IGIB ETF

IGIB ETF Overview

Market Cap in USD 15,056m
Category Corporate Bond
TER 0.04%
IPO / Inception 2007-01-05

IGIB ETF Ratings

Growth 5y 4.41%
Fundamental -
Dividend 55.2%
Rel. Strength Industry 152
Analysts -
Fair Price Momentum 49.52 USD
Fair Price DCF -

IGIB Dividends

Dividend Yield 12m 4.02%
Yield on Cost 5y 4.21%
Annual Growth 5y -0.29%
Payout Consistency 92.5%

IGIB Growth Ratios

Growth Correlation 3m -44.6%
Growth Correlation 12m 83.1%
Growth Correlation 5y -35.8%
CAGR 5y 0.92%
CAGR/Mean DD 5y 0.13
Sharpe Ratio 12m -0.19
Alpha -7.71
Beta 0.28
Volatility 5.62%
Current Volume 1577.1k
Average Volume 20d 2271.6k
What is the price of IGIB stocks?
As of December 27, 2024, the stock is trading at USD 51.55 with a total of 1,577,100 shares traded.
Over the past week, the price has changed by +0.43%, over one month by -0.79%, over three months by -2.46% and over the past year by +3.88%.
Is iShares 5-10 Year a good stock to buy?
Neither. Based on ValueRay Analyses, iShares 5-10 Year is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 4.41 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IGIB as of December 2024 is 49.52. This means that IGIB is currently overvalued and has a potential downside of -3.94%.
Is IGIB a buy, sell or hold?
iShares 5-10 Year has no consensus analysts rating.
What are the forecast for IGIB stock price target?
According to ValueRays Forecast Model, IGIB iShares 5-10 Year will be worth about 53.8 in December 2025. The stock is currently trading at 51.55. This means that the stock has a potential upside of +4.4%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 53.8 4.4%